AAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...

The AAV Innovation Summit 2025, hosted by Form Bio, will bring together top experts in gene therapy to discuss the latest ...

This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience ... world's most innovative pharmaceutical and biotechnology companies, providing viral vector ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

BioViva’s journey in gene therapy began with its use of an adeno-associated virus (AAV) vector. The company’s lead gene therapy, BV-702, is AAV-based and is in preclinical development for ...

Explore a comprehensive guide to standardizing large scale production and clarification of lentiviral vectors.

Gene therapy is usually reserved for severe and ... Here we show that an orally administered adeno-associated viral vector leads to persistent expression of a ß-galactosidase transgene in both ...